|
|
| | Angiotensinogen (1-14) (human) (trifluoroacetate salt) Basic information |
| | Angiotensinogen (1-14) (human) (trifluoroacetate salt) Chemical Properties |
| solubility | Formic Acid: 1 mg/ml |
| | Angiotensinogen (1-14) (human) (trifluoroacetate salt) Usage And Synthesis |
| Description | Angiotensinogen (1-14), also known as tetradecapeptide (TDP), is a synthetic peptide precursor of angiotensin I (Item No. 24737) that corresponds to amino acids 1-14 of endogenous human angiotensinogen.1 Angiotensinogen (1-14) is cleaved by renin at the Leu-Val peptide bond to release angiotensin I, which is then converted to angiotensin II (Item No. 17150) by angiotensin converting enzyme (ACE) and exerts vasoconstrictive properties.2 Angiotensinogen (1-14) (0.001-1 μM) induces contraction of isolated rat femoral resistance vessels, an effect that is reduced by the angiotensin II receptor partial antagonist saralasin and enhanced by the serine protease kallikrein.3WARNING This product is not for human or veterinary use. | | References | [1] RYOICHIRO KAGEYAMA Shigetada N Hiroaki Ohkubo. Primary structure of human preangiotensinogen deduced from the cloned cDNA sequence[J]. Biochemistry Biochemistry, 1984, 23 16: 3603-3609. DOI: 10.1021/bi00311a006
[2] DUANE A. TEWKSBURY James T Richard A Dart. The amino terminal amino acid sequence of human angiotensinogen[J]. Biochemical and biophysical research communications, 1981, 99 4: Pages 1311-1315. DOI: 10.1016/0006-291x(81)90762-2
[3] STINNE KVIST Christian A Michael J Mulvany. Studies of the renin-angiotensin system in the wall of rat femoral resistance vessels[J]. European journal of pharmacology, 1991, 198 1: Pages 77-83. DOI: 10.1016/0014-2999(91)90564-7 |
| | Angiotensinogen (1-14) (human) (trifluoroacetate salt) Preparation Products And Raw materials |
|